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Psychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent in 
Alzheimer disease (AD with psychosis, AD+P). AD+P affects ~50% of individuals with AD, 
identifies a subgroup with poor outcomes, and is associated with a greater degree of cognitive 
impairment and depressive symptoms, compared to subjects without psychosis (AD-P). 
Although the estimated heritability of AD+P is 61%, genetic sources of risk are unknown. We 
report a genome-wide meta-analysis of 12,317 AD subjects, 5,445 AD+P. Results showed 
common genetic variation accounted for a significant portion of heritability. Two loci, one in 
ENPP6 (rs9994623, O.R. (95%CI) 1.16 (1.10, 1.22), p=1.26x10-8) and one spanning the 3’-UTR 
of an alternatively spliced transcript of SUMF1 (rs201109606, O.R. 0.65 (0.56-0.76), p=3.24x10-
8), had genome-wide significant associations with AD+P. Gene-based analysis identified a 
significant association with APOE, due to the APOE risk haplotype ε4. AD+P demonstrated 
negative genetic correlations with cognitive and educational attainment and positive genetic 
correlation with depressive symptoms. We previously observed a negative genetic correlation 
with schizophrenia; instead, we now found a stronger negative correlation with the related 
phenotype of bipolar disorder. Analysis of polygenic risk scores supported this genetic 
correlation and documented a positive genetic correlation with risk variation for AD, beyond the 
effect of ε4. We also document a small set of SNPs likely to affect risk for AD+P and AD or 
schizophrenia. These findings provide the first unbiased identification of the association of 




Psychotic symptoms, defined as the occurrence of delusions or hallucinations,  constitute a 
phenotype within Alzheimer disease (AD+Psychosis, AD+P) that affects ~ 40% to 60% of 
individuals with AD and is associated with poor outcomes.1 In comparison to AD subjects 
without psychosis (AD-P), AD+P subjects have greater cognitive impairments and experience 
more rapid declines in cognition and function that begin prior to psychosis onset.2-9 AD+P is also 
often associated with increased rates of concurrent neuropsychiatric symptoms, including 
agitation,10 aggression,11,12 and depression.5,13-15 As a consequence, AD+P is associated with 
increased rates of other poor outcomes, including greater distress for family and caregivers,16 
higher institutionalization rates,17-20 worse health,21 and increased mortality22 compared to AD-P 
patients.  
 
The AD+P phenotype is well suited for genetic studies when careful attention is paid to 
excluding potential phenocopies of both AD+P and AD-P. For example, we have shown that the 
heritability of AD+P is greatest when requiring the presence of multiple or recurrent psychotic 
symptoms, rather than a one-time occurrence of a single symptom.23 Similarly, because 
psychotic symptoms typically emerge in the transition from mild to moderate stages of AD,5 
individuals without psychosis who are still in the early stages of disease may later manifest 
psychosis, and therefore, need to be excluded from analysis. Using these approaches to 
phenotypic characterization, we have previously reported familial aggregation of AD+P,24 which 
has since been replicated in two independent cohorts.5,25 We further estimated the heritability of 
the presence or absence of psychosis in AD at 61%.23,26  
 
Thus, AD+P is likely to be strongly influenced by genetic variation. To date, no study has 
identified genome-wide significant associations with AD+P, largely due to the small sample 
sizes of prior studies. However, in prior reports we identified negative genetic correlation of 
AD+P risk with risk for schizophrenia.27,28 We now report a large genome-wide association 
meta-analysis of 12,317 AD subjects with and without psychosis. We identified two loci with 
genome-wide significant associations with AD+P, in ENPP6 and SUMF1. In gene-based 
analyses, only APOE (p=1.23x10-6) reached the criterion for genome-wide significance. AD+P 
was negatively genetically correlated with educational attainment and positively with depressive 
symptoms. Surprisingly, AD+P was not significantly genetically correlated with schizophrenia, 
but it was negatively correlated with bipolar disorder. Analysis of polygenic risk scores derived 
from schizophrenia (PRSSZ), and bipolar disorder (PRSBP) GWAS, support these genetic 
correlations. However, the relationship of schizophrenia risk to AD+P appears subtle, with some 
established risk SNPs for schizophrenia likely to confer risk for AD+P, while others confer 
protection.  
 
Materials and Methods 
Subjects 
This study analyzed samples from 12,317 subjects diagnosed with possible, probable,29 and 
when available, autopsy-confirmed definite30 Alzheimer disease (for subject characteristics see 
Table 1A). Diagnoses were made based on diagnostic evaluations, cognitive testing, and in 
some cases neuropathologic assessment, conducted during subjects’ participation in the 
following eight source programs as previously described: the Fundació ACE Barcelona 
Alzheimer Treatment and Research Center (ACE/GR@ACE),31-33 a Consortium of National 
Institute on Aging Alzheimer Disease Centers (ADC),34 Eli Lilly and Company (LILLY),35,36  the 
Norwegian, Exeter and King’s College Consortium for Genetics of Neuropsychiatric Symptoms 
in Dementia (NEXGENS),37-42 the National Institute on Aging’s Late Onset Alzheimer’s Disease 
Family Study (NIA-LOAD),5,26 the National Institute of Mental Health Genetics Initiative AD 
Cohort (NIMH),24 the University of Pittsburgh Alzheimer Disease Research Center (PITT 
ADRC),43,44 and the MRC genetic resource for Late-onset AD included in the Genetic and 
Environmental Risk in AD Consortium  (UK-Cardiff).27,31,45 Collection of clinical data and genetic 
samples were approved by each source program’s local Institutional Review Board or Medical 
Ethics Committee, as appropriate. 
 
Characterization of Psychosis 
Subjects were characterized for the presence or absence of delusions and hallucinations within 
the individual source programs (including their sub-studies) using the CERAD behavioral rating 
scale46 (PITT ADRC and NIA-LOAD), Neuropsychiatric Inventory Questionnaire (NPI-Q,47 NIA-
LOAD, ADC, NEXGENS), NPI-Q Spanish Language Version48 (ACE/GR@ACE), NPI49 (UK-
Cardiff, NEXGENS, LILLY), and Brief Psychiatric Rating Scale50 (NIMH). Each of these 
instruments has established reliability in AD,5,51 and we have previously used all successfully in 
analyses of psychosis in AD subjects.4,5,7,23,43 AD+P was defined by the presence of persistent 
hallucinations or delusions throughout the course of dementia, AD-P was defined by the 
absence of all symptoms at all assessments. However, because psychotic symptoms typically 
emerge in the transition from mild to moderate stages of AD5, individuals without psychosis, but 
who were still in the early stages of disease at their last assessment (CDR® Dementia Staging 
Instrument52 score < 1, mini-mental state examination score53 > 20), were considered to be at 
substantial risk of developing AD+P later in their course. Thus, these individuals were excluded 
from the analysis. We have used these approaches to characterizing and defining AD+P and 
AD-P in multiple studies demonstrating the heritability and association with genetic variation of 
the AD+P phenotype.5,23,24,26-28,54  
 
For additional detail of each source program’s clinical assessment methodology and 




Six of the eight program sources provided us with either blood (ACE/GR@ACE) or DNA 
samples (PITT ADRC, UK-Cardiff, NIA-LOAD, ADC, NIMH), all of which were processed by the 
Genomics Core Lab at the University of Pittsburgh. Genomic DNA was extracted from whole 
blood samples using the Qiamp Blood Mini kit (Qiagen, Valencia, CA). All DNA was quantitated 
by Pico Green (Thermo Fisher, Pittsburgh, PA) and diluted to a DNA concentration of 23ng/µl. 
Samples were genotyped at the Children’s Hospital of Philadelphia (CHoP, Philadelphia, PA) 
using Illumina’s Global Screening Array (Illumina, San Diego, CA). Prior to genotyping, ChoP 
confirmed DNA concentrations by Pico Green assay, and performed WGA on samples when 
necessary.   
 
In addition to the above-mentioned blood and DNA samples, ACE/GR@ACE, LILLY, and NIA-
LOAD provided us with single nucleotide polymorphism (SNP) array data. For the ADC, SNP 
array data was provided by the Alzheimer's Disease Genetics Consortium (ADGC). NEXGENS 
provided genome-wide association (GWA) statistics for the comparison of AD-P and AD+P. 
Additional details of the generation of SNP array data for all programs can be found in the 
Supplementary Material.  
 
Analysis 
Data from the eight program sources were processed as four cohorts (Phase 1, Phase 2, 
GR@ACE, and NEXGENS), based on timing of receipt of the data. Data processing, QC, and 
statistical analyses were uniform across three of the cohorts for which there were genotypes 
(Phase 1, Phase 2, GR@ACE), whereas only summary statistics were available for the fourth 
cohort (NEXGENS).  All cohorts were analyzed separately for GWA, then statistics per SNP 
from these analyses were combined by meta-analysis using METAL.55 Below we describe 
quality control procedures for the three genotyped cohorts. For more detail of other methods 
see the Supplementary Material. Additional details for the NEXGENS cohort have been 
described previously.56 Methods were implemented within Plink57,58 unless otherwise noted. 
 
Quality Control (QC) was completed by both genotype and by sample from Phase 1, Phase 2, 
and GR@ACE. After QC, 6,872 AD-P and 5,445 AD+P subjects, distributed across the four 
cohorts, remained for analysis (Table 1B). We determined ancestry using GemTools analysis59 
of a subset of autosomal SNPs with non-call rate < 0.001 and MAF > 0.05 for Phase 1, Phase 2, 
and GR@ACE. These SNPs were pruned such that, within a 50 SNP block and a 5 SNP step-
size, the linkage disequilibrium r2 < 0.01. For each of the three cohorts, a different subset of 
SNPs was chosen for ancestry analysis, and the resulting ancestry plots were used to identify 
the samples in the major European ancestry cluster. Analysis of NEXGENS56 was restricted to 
individuals of European ancestry using genetic principal components computed by 
EIGENSTRAT.60  
 
Genotypes were imputed using the Sanger Imputation Server,61 the 1000 Genomes Phase3 
reference panel,62 and EAGLE2 for pre-phasing63 for Phase 1, Phase 2, and GR@ACE. Before 
imputation, the genotypes were harmonized using the perl script HRC-1000G-check-bim-
v4.2.5.pl. This resulted in 85,057,462 imputed or genotyped SNPs for each sample. QC of the 
imputed SNPs included the requirement that the INFO score for a SNP in each data set > 0.81; 
MAF > 0.01; and, among all European ancestry subpopulations defined by GemTools, Fst < 
0.005. For NEXGENS phasing and imputation was done via the Sanger Imputation Service 
using the Haplotype Reference Consortium (r1.1) reference panel on all cohorts. After 
imputation, only SNPs with an imputation quality (INFO) score > 0.4 and MAF > 0.05 were 
retained.  
 
Separate GWA analyses were performed for the Phase 1, Phase 2, and GR@ACE cohorts, to 
contrast AD+P versus AD-P for the 9,200,578 SNPs using the Plink option --logistic and with 
adjustment for the three ancestry dimensions (Supplementary Figures S1-S3). For 
chromosome X, an additional covariate for sex was included. For NEXGENS, separate logistic 
regressions, implemented in PLINK for each of the five NEXGENS consortium datasets, were 
used to contrast AD+P versus AD-P for each SNP, with adjustment for the first 10 ancestry 
principal components. METAL software was used to conduct inverse-variance weighted fixed 
effects meta-analysis across the five NEXGENS datasets, applying genomic control,55 to 
generate the summary statistics used in the current analysis. The four GWAS statistics (Phase 
1, Phase 2, GR@ACE, NEXGENS summary), per SNP, were then meta-analyzed using 
METAL.  
 
Heritability of AD+P using GenomicSEM was estimated from 1,126,265 summary statistics from 
our METAL analysis. Of the 7,105,229 SNPs used for GWAS, 1,126,265 matched to those 
available on the GenomicSEM website. Also, using genome-wide complex trait analysis 
(GCTA),64 heritability was estimated from 9,031 subjects of European ancestry drawn from the 
Phase 1, Phase 2, and GR@ACE cohorts for which individual genotypes were available (Table 
1B). Two eigenvectors were used to control for ancestry, 997,105 SNPs were included in the 
analysis.  
 
Individuals of European ancestry from all four cohorts were used to estimate genetic 
correlations using LD Score65 and LD Hub (version 1.9.3).66 We selected phenotypes for 
analysis based on prior studies showing correlations with psychosis in AD (years of schooling, 
depressive symptoms) or  genetic association with AD+P (schizophrenia), or because they are 
closely related with the above phenotypes. Specifically, we included intelligence, which is 
genetically correlated with years of schooling and bipolar disorder which is strongly genetically 
correlated with both depressive symptoms and schizophrenia. Finally, we included AD as it is a 
necessary condition of AD±P, and two other neurodegenerative diseases, amyotrophic lateral 
sclerosis (ALS) and Parkinson’s disease, each of which is associated with a neuropathology 
that may contribute to psychosis risk in AD. 
 
We evaluated how well three different polygenic risk scores could differentiate 9,031 AD+P and 
AD-P subjects of European ancestry. We used the pruning and thresholding approach67 to 
compute a PRS for our subjects, developed from GWAS results for AD (PRSAD), 
42 
schizophrenia (PRSSZ),
68 and bipolar disorder (PRSBP),
69 separately. We used a set of GWAS p-
value thresholds for SNP inclusion in each score (5x10-8, 0.0001, 0.001, 0.01, 0.1, 0.2, 0.3, 0.4, 
0.5).  
Gene-based analyses were performed on the summary association statistics using the most 
recent version (1.08b) of MAGMA.70 For the primary analysis, SNPs were assigned to genes if 
they lay within the gene boundaries (as defined by NCBI) and the MAGMA “mean” method was 
used to derive the gene-wide association statistic (the sum of the squared Z statistics for 
individual SNPs). A secondary analysis assigned SNPs to genes if they lay within 35kb 
upstream or 10kb downstream of the gene boundary, to capture regulatory regions.71 
 
Gene set enrichment analyses were performed in MAGMA,70 correcting for the number of SNPs 
in each gene, linkage disequilibrium (LD) between SNPs and LD between genes. The measure 
of pathway enrichment is the MAGMA “competitive” test (where the association statistic for 
genes in the pathway is compared to those of all other protein-coding genes).72  
 
Transcriptome-wide association (TWAS) was implemented using the FUSION package73 was 
used to perform a TWAS using dorsolateral prefrontal cortex expression data from the 
CommonMind Consortium and expression data from 13 Brain tissues from the GTEx 
(Genotype-Tissue expression) consortium ( v7).74 Results were corrected for multiple testing of 
multiple genes within each tissue using the Bonferroni method.  
 





A total of 12,317 subjects, 6,872 AD-P and 5,445 AD+P, were included in this GWAS analysis 
(Table 1A). Contrasting AD-P to AD+P genotypes across the genome revealed two significant 
loci (Figure 1, Supplementary Table S1). One locus was at 4q24, mapping to an intron of 
ENPP6 (best SNP rs9994623, O.R. (95%CI) 1.16 (1.10, 1.22), p=1.26×10-8). The other locus 
was at 3p26.1 (best SNP rs201109606, O.R. 0.65 (0.56-0.76), p=3.24×10-8). This locus spans 
the 3’ untranslated region (3’-UTR) of an alternatively spliced variant of SUMF1 (SUMF1-204 
ENST00000448413.5). None of the SNPs showing significant association in these loci are 
annotated as expression quantitative trait loci (eQTL) in GTEx. Behavior of the association 
statistics, as assessed by probability-probability plot (Supplementary Figure S4), is consistent 
with the expectation for such analyses, and the genomic control estimate,75 GC=1.03, shows no 
evidence for confounding by ancestry.  
 
For the gene-based tests (Supplementary Table S2), only APOE (p=1.23×10-6) reached the 
criterion for genome-wide significance (p<2.5×10-6).76 This association was only significant for 
SNPs within APOE itself. When the 35/10kb window around genes was used to assign SNPs, 
no genes reached genome-wide significance. There was substantial association signal for SNPs 
in and near APOE, however: the smallest p-value achieved was at rs283811 (z = 5.15, p = 
2.55×10-7), which falls in an intron of NECTIN2 (PVRL2 protein). The second smallest p-value 
occurred for rs429358 (z = 5.12, p = 2.96×10-7), which is one of the two SNPs comprising the 
APOE risk haplotype ε4. These two SNPs, separated by 23,441 bp, were in modest LD (r2 = 
0.52, D’ = 0.9177) in the 1000G CEU population sample. To determine if ε4 count could explain 
the AD+P association signal at this locus, we first analyzed a subset of our subjects who were 
characterized for the ε4 haplotype (2414 AD+P and 2509 AD-P) by logistic regression of AD+P 
status (yes/no) on ε4 count, after controlling for three eigenvectors for ancestry. The odds 
increased significantly with count of ε4 haplotypes (OR = 1.21; 95% CI: 1.11-1.31; p = 8.64×10-
6). Of the 537 SNPs in this locus, none achieved a p-value<0.0001 in this logistic model after 
controlling for ε4 count and ancestry (rs2927472 achieved the smallest p-value, 0.00053). Next, 
using the same subjects, we determined the LD of ε4, in terms of r2, with 120 SNPs in the APOE 
locus, all of which had association statistic |z| > 2.0 based on the GWAS of AD+P. We then 
regressed the statistics for these SNPs, |z|, on their LD with ε4, yielding a strongly positive slope 
(b=3.14, p = 1.90×10-41) and explaining 78.5% of the variance in the observed AD+P z-statistics. 
Thus, we conclude that the preponderance of AD+P association signal in this locus arises from 
ε4. 
 
For the pathway enrichment analyses (Supplementary Table S3), only the Pathway Interaction 
Database (PID) IGF1 pathway showed significant enrichment after correction for multiple testing 
(p=1.17×10-6, q=0.011), although it was no longer significant when the 35/10kb window was 
used (p=0.0469, q=0.920). Interestingly, one of the pathways found to be significantly enriched 
for AD risk in Kunkle et al.78 (GO:48156, tau protein binding) showed significant enrichment 
(p=6.44×10-4 and p=2.21×10-3 respectively), albeit not withstanding correction for multiple 
testing. Given that this pathway includes APOE, the enrichment analysis was repeated 
excluding genes within 1Mb of APOE (a total of 70 genes), with results shown in 
Supplementary Table S3. Removing the genes in the APOE region greatly reduced the 
significance of GO:48156 (p=0.0106), suggesting that its enrichment is mainly due to APOE.  
 
TWAS comprised a total of 44,185 gene-tissue combinations (Supplementary Tables S4 and 
S5). No TWAS association was significant after correction for the number of tests performed in 
all genes and tissues combined (p<1.13×10-6, Bonferroni correction for 44,185 tests). Two 
associations were significant after Bonferroni correction for the number of genes tested in their 
particular tissue: VN1R108P in GTEx7 hippocampus (p=2.94×10-6) and FAM182B in GTEx7 
cerebellum (p=5.51×10-6). For both genes, an increase in gene expression was associated with 
the presence of psychosis. 
 
SNP-Based Heritability 
While earlier studies the AD+P phenotype have shown strong clustering in families and 
substantial heritability, SNP-based heritability has not been estimated. We estimated it in two 
ways. First, by analyzing our GWAS statistics using GenomicSEM, SNP-based heritability was 
estimated at 0.181 ±  0.064 (Chi-square = 8.0, df=1, p = .005). An alternative approach, using 
the GCTA software, evaluated genotypes genome-wide to determine relationships among the 
samples and how they partitioned within and between AD+P and AD-P sets. This estimate was 
0.312 ±  0.053 (Chi-square = 34.98, df=1, p = 3.3×10-9). The larger estimate probably arises due 
to greater information contained in estimated genetic relationships, relative to our modestly 
powered GWAS, although the heritability estimates are not significantly different. The GCTA 
analysis focused on subjects of European ancestry, genetically determined, to avoid 
confounding of ancestry.  
 
 
Genetic Correlation, Polygenic Risk Score, and Risk SNP Analyses 
Subjects of European ancestry were also used to estimate genetic correlations of AD+P with 
select phenotypes available from LD Hub (Table 2). Consistent with clinical observations, AD+P 
is significantly genetically correlated with “Years of Schooling” (and nearly so with the related 
phenotype, “Intelligence”) and with “Depressive Symptoms”. In contrast, AD+P was not 
significantly genetically correlated with AD (Table 2).  Nor was AD+P significantly genetically 
correlated with the two other neurodegenerative disorders evaluated, ALS and Parkinson 
disease (Table 2). 
 
We previously found a significant relationship between risk for AD+P and schizophrenia.28 
Specifically, we genotyped 94 of 128 SNPs that showed genome-wide-significance for 
association with schizophrenia in a sample of AD+P subjects. We constructed a predictive score 
for schizophrenia risk from these SNPs, then assessed whether this score predicted AD+P 
status in the AD sample. There was a significant negative correlation between the risk score for 
schizophrenia and AD+P status, which we then replicated by genotyping 60 of the 94 risk SNPs 
in an independent sample. Now, using SNPs from across the genome and a larger set of AD 
subjects, results from LD HUB show a negative, but non-significant, genetic correlation with 
schizophrenia, while showing a negative and significant genetic correlation with bipolar disorder 
(Table 2). In fact, no SNP with p value <10-4 for association with psychosis in AD had a p value 
<10-5 in the 108 loci associated with schizophrenia.79 
 
Because bipolar disorder and schizophrenia are genetically correlated, we next asked if our 
original result for the 94 SNPs could be explained by an overlap of risk SNPs for schizophrenia 
and bipolar disorder. To do so, we tested whether the odds ratios for association of these SNPs 
for these disorders69,79 were independent. They were not (Supplementary Figure S5); 91 of 94 
SNPs had odds ratios exceeding one for both disorders, whereas 47 were expected under 
independence (sign test, p = 5.8×10-20).   
 
Given the somewhat surprising results for the genetic correlations of AD+P with schizophrenia, 
bipolar disorder, and AD, we examined whether PRS scores for each of these disorders could 
differentiate AD+P versus AD-P subjects. In agreement with the genetic correlation, the PRSBP 
differentiated AD+P from AD-P, whereas PRSSZ showed little ability to differentiate AD+P from 
AD-P subjects (Table 3).  
 
By contrast, the PRSAD did not agree with the genetic correlation of AD and AD+P from LD Hub. 
PRSAD significantly predicted AD+P status, in the direction of increased risk for AD+P (Table 3). 
Even when we removed the SNP representing the APOE locus, predictions remained positive 
(Supplementary Table S6). Yet the genetic correlation between our AD+P GWAS and 
Alzheimer’s disease, as estimated in LD HUB, was negative, although non-significant. Notably, 
PRSAD was built on results from a larger AD GWAS
42 than LD Hub uses.45 Thus, we conjectured 
perhaps sample size explains the difference. However, when we computed PRSAD using the 
GWAS data from45, it predicts AD+P as well as PRSAD from the larger GWAS, if not better (cf 
Supplementary Table S7 with Table 3)  Notably, when we analyzed the genetic correlation of 
the two AD studies in LD Hub, the genetic correlation was 0.9 with standard error of 0.11. Thus, 
it seems likely that the difference between the genetic correlation estimated by LD HUB and the 
results for PRSAD trace to the genetic architecture of AD and differences in power for each 
method.   
 
Because “uncorrelated” is not the same as “independent”, we evaluated one more dimension of 
these data. Specifically, we evaluated the GWAS-significant SNPs (GWAS SNPs) for 
schizophrenia,68 bipolar disorder,69 and AD42 to determine whether they also had signal in our 
AD+P GWAS. We approached this question in two ways. First, we queried the GWAS SNPs to 
determine if their p-values for AD+P were less than 10-4: Eleven SNPs crossed the threshold, all 
in the APOE locus and all associated with AD. Next, we reasoned that if some GWAS SNPs 
also generated risk for or protection from AD+P, whereas others did not, then those AD+P 
statistics would be represented by a mixture of distributions. We found support for a mixture of 
distributions for schizophrenia and separately for AD (Supplementary Figures S6-S8), while 
for bipolar disorder there were too few independent GWAS SNPs to have any confidence in our 
results (See Supplementary Methods for details). Curiously, while AD GWAS SNPs were 
consistent in their effects on AD and AD+P, effects of schizophrenia GWAS SNPs were not. 
Instead, risk alleles for schizophrenia could impart risk or protection for AD+P (Supplementary 
Methods and Supplementary Figure S9).  In addition, using the mixture model results, we 
identified a small set of SNPs likely to affect risk to AD+P and either AD or schizophrenia 
(Supplementary Table S8). 
 
Discussion 
We identified evidence of genome-wide significant association with psychosis risk in AD at 
SNPs within ENPP6, and in the 3’-UTR of an alternatively spliced transcript of SUMF1. 
Exploration of multiple data sets did not reveal any current evidence linking the SNPs at these 
loci to variation in expression of ENPP6, SUMF1, or other genes. Similarly, although the 
alternatively spliced SUMF1-204 transcript is expressed in brain,80 AD+P risk SNPs in the 
SUMF1 locus were not associated with brain expression of SUMF1-204 (S. Sieberts, Personal 
Communication). Nor were SNPs at these loci linked to other potential genetic mechanisms, 
such as variation in epigenetic modifications. However, we note that for SUMF1, the locus is in 
the 3’-UTR, a region that often serves a substantial role in regulating protein levels via post-
transcriptional mechanisms.81   
 
ENPP6 encodes a glycerophosphodiesterase that is highly expressed in new oligodendrocytes 
as they differentiate from their precursors.82 Recent data in mice have demonstrated that 
differentiation of oligodendrocytes from their precursors (as indicated by increased ENPP6 
mRNA expression) is a necessary component of early,83 i.e. synaptic,84 phases of new (motor) 
learning. ENPP6 protein can be expressed both on the myelin membrane and as a soluble form 
that is found extracellularly.85,86 ENPP6 acts as a hydrolase that severs choline from substrates, 
including lysophosphatidylcholine, glycerophosphorylcholine, and 
sphingosylphosphorylcholine.86 Of these, it has highest catalytic efficiency towards 
sphingosylphosphorylcholine,85 releasing both sphingosine and phosphocholine. Sphingosine is 
phosphorylated to generate sphingosine-1-phosphate, which signals via the g-protein-coupled 
sphingosine-1-phosphate receptor (S1PR1). It is of some interest, therefore, that the S1PR1 
modulator, fingolimod,87 has been previously shown to increase excitatory synaptic 
transmission88 and improve psychosis-associated behaviors in a genetic animal model of β-
amyloid overproduction.89  
 
The locus on chromosome 3 maps to introns spanning the 3’-UTR of an alternatively spliced 
transcript of SUMF1. SUMF1 encodes formylglycine-generating enzyme, which serves as a 
master activator of lysosomal sulfatases by converting conserved cysteines to formylglycine in 
their active sites. As a consequence, genetic disruption of SUMF1 leads to a multiple sulfatase 
deficiency syndrome.90,91 Importantly, the transcript of SUMF1 (SUMF1-204, 
ENST00000448413.5), within which our locus is located, encodes an isoform of formylglycine-
generating enzyme (isoform 3, Uniprot Accession Q8NBK3-3) lacking the enzymatically active 
Cys341 residue.92 The functional consequences of this change are not established, but would 
be anticipated to reduce or eliminate the primary enzymatic function. The function of the novel 
sequence that replaces the c-terminal of formylglycine-generating enzyme in isoform 3 is also 
not known, and BLAST of this sequence against the UNIPROT database does not identify 
homologous proteins. Nevertheless, speaking to the potential functional impact in AD+P, 
ENST00000448413.5 is detectable in cerebral cortex.80  
 
Recently, an appreciation of how lysosomal storage dysfunction also leads to impaired 
autophagy has emerged.93 It is thus not surprising, therefore, that selective depletion of SUMF1 
in either astrocytes or neurons results in neurodegeneration.94 How alterations in function of 
formylglycine-generating enzyme, due to a potential change in levels of isoform 3, may modify 
the course of AD through these mechanisms, and thus result in the AD+P phenotype, remains 
speculative. We have previously shown, however, that preservation of synaptic protein levels in 
the context of AD neuropathology is associated with reduced psychosis risk.89 Thus, genetic 
alterations that impact degradation of synaptic proteins by the lysosome to autophagosome 
pathway are likely to influence risk of psychosis.  
 
We and others34 have previously evaluated the association of psychosis in AD with APOE risk 
haplotype ε4, finding inconsistent evidence of association.34 Our current findings, obtained from 
by far the largest cohort to address this question, shed further light on these prior observations. 
We found that SNPs within APOE demonstrate gene-based significant association with AD+P, 
and that this association appears attributable to the presence of the ε4 haplotype itself, without 
a detectable contribution from other SNPs.  Because the impact of ε4 on AD+P risk is not large, 
increasing the odds by 1.21, prior inconsistent associations with AD+P likely resulted from the 
much smaller sample sizes in all prior studies.  
 
APOE ε4 has been shown to increase the accumulation of amyloid β and phosphorylated tau, 
and, even in the absence of Aβ overproduction, lead to reductions in dendritic markers and 
synaptic proteins.95 For example, we have shown that human ε4 carriers and mice with targeted 
replacement of ε4 had down-regulation of numerous glutamate signaling and synaptic 
proteins.96 Increased phosphotau and reduced synaptic proteins (but not altered amyloid β 
accumulation) have all been associated with psychosis in AD.97 Future human and animal 
model studies of ε4 that control for the contribution of other loci to the genetic risk for AD+P 
would be helpful in determining the relative contributions of these mechanisms to AD+P. 
 
We previously identified, and independently replicated, an inverse association between 
polygenic risk for schizophrenia, defined by a limited set of schizophrenia risk SNPs79, and risk 
for psychosis in AD.28 It was thus somewhat surprising that we saw a non-significant genetic 
correlation between these two disorders when considering both a larger set of SNPs and a 
substantially enlarged cohort of AD subjects with and without psychosis. Instead, we identified a 
negative genetic correlation with risk for bipolar disorder, a disorder that has substantial genetic 
overlap with schizophrenia. Because our prior analyses relied on a subset of SNPs significantly 
associated with risk for schizophrenia, and this set also shows enrichment for affecting risk for 
bipolar disorder (Supplementary Figure S5), this overlap probably explains the discrepancy we 
now observe between our earlier results and the current results for genetic correlations. 
However, the lack of genetic correlation of AD+P with schizophrenia conceals an underlying 
complexity.  We observed that schizophrenia risk SNPs evidenced significant mixture regarding 
AD+P risk, such that risk alleles for schizophrenia could impart risk or protection for AD+P.  
 
In contrast, we observed a positive correlation between genetic risk for depressive symptoms 
and AD+P, consistent with clinical observations of co-occurrence of depressive and psychotic 
symptoms in AD patients,5,13-15 and evidence that antidepressant medications may have some 
effect in reducing psychotic symptoms in AD.98,99 We also observed a significant negative 
genetic correlation of educational level with psychosis risk in AD, and a similar pattern, but not 
quite significant relationship with intelligence. Greater cognitive impairment increases the risk for 
psychosis in AD; moreover, psychosis in AD is further associated with a more rapid rate of 
cognitive decline2-9 (see also review in100). The current findings extend these earlier 
observations, by showing genetic overlap with measures that may be better construed as 
indicative of cognitive reserve, as they reflect early life cognitive attainment. Cognitive reserve 
has long been recognized as protective against developing a degree of cognitive and functional 
impairment sufficient to lead to a diagnosis of AD.101 However, somewhat counter-intuitively, 
once AD is diagnosed, individuals with greater cognitive reserve decline more rapidly.101 Thus, 
the genetic correlations we observed may point to a biology underlying the presence of greater 
cognitive impairment in AD, but not the more rapid decline associated with AD+P. 
 
The above findings are subject to several potential limitations. Although our analysis is the 
largest GWA study of AD+P to date, it is nevertheless modest in sample size in comparison to 
studies of related complex traits.78,79 As our heritability results show, a substantial increase in 
sample size will identify many additional loci as having a significant association with psychosis 
risk in AD. Similarly, increased sample size is needed to provide the necessary power to identify 
genes, transcripts, genetically correlated traits, and pathways in the corresponding analyses 
that derive from the SNP-based associations.  
 
One of our GWAS-significant SNPs, rs201109606, falls in a genomic region marked as simple 
repeats. Perhaps because the SNP is difficult to impute, it did not pass QC for some of our data. 
Nonetheless, the largest two of the four datasets contribute to this result and the estimates of 
the odds ratios for the two data sets are remarkably similar, 0.684 and 0.637. Moreover, other 
SNPs at this locus also support the findings (Supplementary Table S1), although those 
associations are not quite GWAS significant. Thus, this result requires replication.  For 
additional discussion of other findings and potential limitations, see Supplementary Material. 
 
Currently established treatments for psychosis in AD patients are suboptimal, perhaps reflecting 
in part that these treatments were not derived to prevent or reverse an identified biology of 
AD+P.100 The development of effective, specific, therapeutic targets will therefore require as a 
first step delineating this underlying biology. Our study provides the first unbiased evidence of 
association of specific genetic loci with psychosis in AD and can thus serve as an initial road 
map to AD+P biology. These findings, in conjunction with available functional genomic and post-
mortem data, provide multiple links to mechanisms influencing synaptic function as contributors 
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Figure 1. SNP associations with psychosis in AD. A. Manhattan plot. The x-axis shows 
genomic position for autosomes and the X chromosome. The y axis shows statistical 
significance as −log10 (P). Each point represents an analyzed SNP. The dashed horizontal line 
represents the threshold for genome-wide significance (p = 5 x 10-8). B-C. Zoom plots of the 
two genome-wide significant loci. The x-axis shows genomic position. The left y-axis shows 
statistical significance as −log10 (P). Each point represents an analyzed SNP, coded by degree 
of linkage disequilibrium relative to the most significant SNP within the locus. Recombination 
rate through the region is shown on the right y axis. AD: Alzheimer Disease; LD: linkage 
disequilibrium; cM: centimorgans; Mb: megabase 
 
  













N (%) or Mean (SD) 
Female 4,008 (58.3) 3,649 (67.0) 7,657 (62.2) 
Age of Onset2 74 (8.3) 73.4 (8.0) 73.8 (8.2) 
Age at Consent 75.6 (7.0) 77.0 (6.9) 76.2 (7.0) 
Age at Last Visit2 80.5 (8.1) 81.3 (7.7) 80.9 (7.9) 
Last MMSE2 16.0 (6.5) 13.7 (6.8) 15.0 (6.8) 
Last CDR2  
0.0 2 (0.0) 5 (0.1) 7 (0.1) 
0.5 244 (3.8) 186 (3.8) 430 (3.8) 
1.0 2,469 (38.4) 967 (19.6) 3,436 (30.2) 
2.0 1,560 (24.3) 1,586 (32.2) 3,146 (27.7) 
3.0 986 (15.3) 1,340 (27.2) 2,326 (20.5) 
4.0 759 (11.8) 482 (9.8) 1,241 (10.9) 
5.0 410 (6.4) 363 (7.4) 773 (6.8) 
AD-P: Alzheimer disease without psychosis; AD+P: Alzheimer disease with psychosis; MMSE: 
Mini mental state exam; CDR: CDR® Dementia Staging Instrument; 1See Supplementary 
Table S9 for psychosis status by individual program; 2Data not available for some 
subjects/source programs; see Supplementary Tables S10-S17 for details. 
 
 
Table 1B. Sample size for each cohort contributing to the meta-analysis. 
GWA Phase 1 Phase 2 GR@ACE NEXGENS Total 
Diagnosis AD-P AD+P AD-P AD+P AD-P AD+P AD-P AD+P AD-P AD+P 
ALL 3529 3525 1045 495 1646 762 652 663 6872 5445 
EUR 2665 2732 833 394 1646 762 652 663 5796 4551 
GWA: Genome-wide association; AD-P: Alzheimer disease without psychosis; AD+P: Alzheimer 
disease with psychosis; EUR: European ancestry; GR@ACE: Genome Research at Fundacio 
ACE; NEXGENS: Norwegian, Exeter and King’s College Consortium for Genetics of 
Neuropsychiatric Symptoms in Dementia 
 
  
Table 2. Genetic correlations (rg) of psychosis in Alzheimer disease with selected 
relevant phenotypes. Correlations were obtained from LD Hub.66 Phenotypes in bold were 
chosen, a priori, based on phenotypic or genetic (schizophrenia, bipolar disorder) analyses. 
Phenotype rg Se Z p-value 
Alzheimer disease -0.374 0.321 -1.168 0.243
Amyotrophic lateral sclerosis -0.307 0.300 -1.021 0.307
Parkinson disease 0.142 0.186 0.763 0.446
Years of schooling -0.312 0.111 -2.816 0.005
Intelligence -0.200 0.121 -1.650 0.099
Schizophrenia -0.094 0.081 -1.164 0.244
Depressive symptoms 0.327 0.141 2.316 0.021
Bipolar disorder -0.287 0.145 -1.976 0.048
 
  
Table 3. Prediction of psychosis in Alzheimer disease by polygenic risk scores built 
using GWAS results for Bipolar disorder, Schizophrenia, and Alzheimer disease, and the 
pruning and thresholding approach. 
Bipolar Disorder 
P Value Cut Off N OR l95 OR u95 OR P Value R2 
0.00000005 22 0.968 0.928 1.010 0.13 3.30×10-3
0.0001 785 0.961 0.921 1.003 0.065 3.47×10-3
0.001 3112 0.980 0.938 1.023 0.35 3.09×10-3
0.01 14748 0.959 0.918 1.002 0.064 3.47×10-3
0.1 79818 0.950 0.908 0.994 0.025 3.71×10-3
0.2 134250 0.955 0.913 0.999 0.045 3.56×10-3
0.3 182119 0.953 0.911 0.997 0.035 3.62×10-3
0.4 225630 0.957 0.915 1.001 0.056 3.51×10-3
0.5 265136 0.958 0.916 1.002 0.060 3.49×10-3
Schizophrenia 
P Value Cut Off N OR l95.OR u95.OR P Value R2 
0.00000005 329 1.051 1.008 1.096 0.021 8.02×10-4
0.0001 3161 1.012 0.970 1.056 0.57 4.73×10-5
0.001 8488 1.009 0.967 1.052 0.69 2.36×10-5
0.01 26064 1.004 0.962 1.048 0.84 5.80×10-6
0.1 99775 1.006 0.963 1.052 0.78 1.14×10-5
0.2 153878 1.007 0.963 1.053 0.76 1.42×10-5
0.3 198913 1.009 0.965 1.055 0.70 2.24×10-5
0.4 238902 1.011 0.967 1.057 0.62 3.60×10-5
0.5 274264 1.013 0.969 1.059 0.57 4.88×10-5
Alzheimer Disease 
P Value Cut Off N OR l95.OR u95.OR P Value R2 
0.00000005 63 1.088 1.043 1.135 9.75×10-5 2.28×10-3
0.0001 488 1.048 1.005 1.093 2.85×10-2 7.18×10-4
0.001 1962 1.059 1.015 1.105 7.76×10-3 1.06×10-3
0.01 12301 1.069 1.025 1.115 1.99×10-3 1.43×10-3
0.1 83722 1.095 1.050 1.142 2.30×10-5 2.69×10-3
0.2 144621 1.096 1.051 1.143 2.12×10-5 2.71×10-3
0.3 195758 1.096 1.051 1.143 2.07×10-5 2.72×10-3
0.4 239694 1.088 1.043 1.134 9.39×10-5 2.29×10-3
0.5 277645 1.088 1.043 1.135 8.80×10-5 2.30×10-3
 
P Value Cut Off: GWAS p-value threshold used for SNP included in calculating the PRS; N: 
number of SNPs meeting the threshold; OR: Odds ratio; l95 OR: lower limit of the 95% 
confidence interval for OR; u95 OR: upper limit of the 95% confidence interval for OR; R2: partial 






NCBI RS names https://ftp.ncbi.nih.gov/snp/redesign/latest_release/VCF/ 
LD-Hub: http://ldsc.broadinstitute.org/LD Hub/  
Sanger Imputation Service: https://imputation.sanger.ac.uk 
Psychiatric Genetics Consortium: https://www.med.unc.edu/pgc/ 
Imputation preparation: https://www.well.ox.ac.uk/~wrayner/tools/ 
CMC/AMP-AD eQTL Meta-analysis: https://www.synapse.org/#!Synapse:syn16984815 
NCBI gene2go file: ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/  
Reactome: https://reactome.org/download-data  
Gene Ontology: http://geneontology.org/docs/download-ontology/  
Molecular Signatures Database: https://www.gsea-msigdb.org/gsea/msigdb/index.jsp  
R package qvalue: http://github.com/jdstorey/qvalue  
LD Score Regression (LDSC) software v1.0.0 : https://github.com/bulik/ldsc  
HapMap 3 https://www.sanger.ac.uk/resources/downloads/human/hapmap3.html 
Common mind consortium: https://www.nimhgenetics.org/resources/commonmind 
FUSION software  http://gusevlab.org/projects/fusion/ 
 

